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In the present study we investigated, through immunohisto-
chemistry, the presence and location of neurotensin receptor
1 (NTR1) in the peripheral ganglia and carotid body of 16
humans and 5 rats.In both humans and rats,NTR1 immunos-
tained ganglion cells were found in superior cervical ganglia
(57.4±11.6% and 72.4±11.4%,respectively,p<0.05),enteric
ganglia (51.9±10.4% and 64.6±6.1%,p<0.05),sensory gan-
glia (69.2±10.7% and 73.0±13.1%, p>0.05) and parasym-
pathetic ganglia (52.1±14.1% and 59.4±14.0%, p>0.05),
supporting a modulatory role for NT in these ganglia.Positivity
was also detected in 45.6±9.2% and 50.8±6.8% of human
and rat type I glomic cells, respectively, whereas type II cells
were negative. Our findings suggest that NT produced by type
I cells acts in an autocrine or paracrine way on the same cell
type, playing a modulatory role on chemoception.
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N
eurotensin (NT) is a tridecapeptide which
was first isolated from bovine hypothalamus
(Carraway and Leeman, 1973) and is wide-
ly distributed in the nervous system and intestine.In
the nervous system, neurotensin acts as a neuro-
transmitter and neuromodulator (Dobner, 2006); in
the periphery, as a paracrine or endocrine factor
(Mazzocchi et al., 1997; Malendowicz, 1998). It
also acts as a growth factor on various cell types
(Malendowicz, 1993; Markowska  et al., 1994a,
1994b; Evers, 2006).Three different NT receptors,
termed NTR1, NTR2 and NTR3, have been identi-
fied and cloned to date. NTR1 and NTR2 are,
respectively, high- and low-affinity seven trans-
membrane domain G protein-coupled receptors.
NTR3 is a high-affinity single trans-membrane
domain type 1 receptor, with 100% homology with
the sorting protein, gp95/sortilin (Kitabgi, 2006;
Mazella  et al., 1998). NTR3 can also form het-
erodimers with NTR1 in the plasma membrane
(Martin et al.,2002).Nuclear internalization of the
NTR1 has been reported and has been suggested to
play a role in the production of long-term genomic
effects (Feldberg et al., 1998; Laduron, 1992). It
has also been reported that NTR2, but not NTR1,
returns to the plasma membrane after NT-induced
sequestration (Mazella and Vincent, 2006).
In the peripheral nervous system, pregangliar
fibers containing NT have been found in sympathet-
ic, parasympathetic and enteric ganglia, and func-
tional studies also suggest the expression of NTRs
in ganglion cells. However, direct evidence of NTR1
protein expression in the different cell types of the
ganglia has not yet been provided for human and
rat. Only in rat dorsal root ganglia has evidence of
NTR1 expression been given through hybridization
in situ (Zhang et al., 1995), but there are no data
on protein location or internalization.
The carotid body is an arterial chemoreceptor,
sensitive to reductions in partial blood oxygen pres-
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                 sure and pH and to increases in partial CO2 pres-
sure, the stimulation of which induces increases in
ventilatory frequency and volume.The carotid body
is situated at the carotid bifurcation, and is com-
posed of parenchymal lobules separated by connec-
tive tissue, in which afferent fibers of the glosso-
pharyngeal nerve, arising from the petrosal gan-
glion,occur (Porzionato et al.,2005).Two different
cell populations are present in the carotid body:
type I cells, in turn separated into light, dark and
pyknotic, and type II cells, at the edges of the clus-
ters. Post-ganglionic sympathetic nerve fibers from
the superior cervical ganglion are present,innervat-
ing blood vessels and type I cells, and preganglion-
ic parasympathetic and sympathetic fibers reaching
ganglion cells near the glomic cells. NT has been
detected in glomic cells (Heath et al., 1988; Heym
and Kummer, 1989; Smith et al., 1990) but the
presence of the corresponding receptors in the var-
ious glomic cell types has not yet been investigated.
Thus, the aim of the present study was to investi-
gate, through immunohistochemistry, the presence
and location of NTR1 in the peripheral ganglia and
carotid body of both human and rat, with particu-
lar reference to the different cell types.
Materials and Methods
Materials consisted of dorsal root ganglia,
trigeminal ganglia,superior cervical ganglia,enteric
(both myenteric and submucous) ganglia, and
carotid bodies obtained at autopsy from 16 adult
subjects (10 males, 6 females; mean age 44.3
years, Standard Deviation (SD) ± 3.4), clinically
negative for chronic pulmonary or cardiovascular
diseases, and from 5 adult Wistar rats weighing
200-250 g. Samples for evaluation of enteric gan-
glia were taken at the level of the first jejunal loop.
Further materials consisted in ciliary ganglia sam-
pled from the above rats and pelvic ganglia sampled
from the above humans. Autopsies were performed
between 24 and 30 hours after death. Sampling
from rats was performed soon after sacrifice.
Samples were fixed in neutral 10% formalin and
embedded in paraffin wax. Immunohistochemical
examination was carried out on 3 µm thick sec-
tions. Sections were incubated in 0.3% hydrogen
peroxide for 10 min at room temperature, to
remove endogenous peroxidase activity, and then in
blocking serum (0.04% bovine serum albumin
(A2153, Sigma-Aldrich, Milan, Italy) and 0.5%
normal goat serum (X0907, Dako Corporation,
Carpinteria, CA, USA) in PBS) for 30 min. NTR1
immunoreactivity was detected with a rabbit poly-
clonal anti-NTR1 antibody at 1:600 dilution in
blocking serum for 1 hour at room temperature.
This antibody was raised against amino acids 1-28
and 50-69 of rat NTR1 and also detected human
NTR1 (Brun et al., 2005). Sections were then
washed twice for 5 min in phosphate buffered saline
(PBS), revealed with anti-rabbit serum for 20 min
(DAKO
® EnVision + TM Peroxidase, Rabbit, Dako
Corporation, Carpinteria, CA, USA), and developed
in 3,3’-diaminobenzidine (DAB, Sigma-Aldrich,
Milan, Italy). Lastly, sections were counterstained
with hematoxylin. Negative controls were per-
formed by omission of primary antibody. NTR1
immunoreactions detected in rat and human sub-
stantia nigra were used as positive controls.
Immunohistochemistry anti-tyrosine hydroxylase
(TH) was used to distinguish between sympathetic
(TH-positive) and parasympathetic (TH-negative)
human pelvic ganglia (Keast et al., 1995).To block
endogenous peroxidase activity,rehydrated sections
were incubated in 0.3% hydrogen peroxide for 10
min at room temperature and then predigested with
0.1% trypsin for antigen retrieval.After 2 rinses in
PBS, sections were incubated for 30 min in block-
ing serum at room temperature to suppress nonspe-
cific binding.Thereafter, sections were incubated in
monoclonal mouse anti-human TH (DiaSorin,
Stillwater,MN,USA,1:1000,raised to TH purified
from rat PC12 cells) overnight at 4C° and in
biotinylated rabbit anti-mouse antibody (Elite
Vecta Stain ABC Kit, Vector Laboratories, CA,
1:200) for 30 min. Lastly, sections were developed
in 3,3’-diaminobenzidine (DAB, Sigma-Aldrich,
Milan, Italy).
In the peripheral ganglia and carotid bodies, per-
centages of ganglion and glomic (types I and II)
NTR1-positive cells, respectively, were evaluated at
a magnification of 40X, and 5 sections and 3 fields
per section were examined. Mean percentages were
calculated for each case and for the entire series.
For each human case, an average of 100 neurons
were counted for sympathetic,parasympathetic and
sensory ganglia,40 neurons for enteric ganglia,200
type I cells for carotid body. For each rat, an aver-
age of 200 neurons were counted for sympathetic
and sensory ganglia, 150 neurons for parasympa-
thetic ganglia, 50 neurons for enteric ganglia, 300
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hematoxylin permitted differentiation between the
light, dark and pyknotic cells of the carotid body,
showing both positive and negative immunoreac-
tions, according to the morphological characteris-
tics and staining properties of the cells.The percent-
ages of dark,light and pyknotic cells showing NTR1
immunoreactivity were evaluated at a magnifica-
tion of 40X, and 5 sections and 3 fields per section
were examined. The mean percentages of positive
dark, light and pyknotic cells were then calculated
for each case and for the entire series.
The Mann-Whitney U-test was performed to ver-
ify any differences in NTR1 immunoreactivity
between human and rat samples and different types
of carotid body cells and of sensory,enteric,sympa-
thetic and parasympathetic ganglionic cells. In
order to reveal differences between glomic type I
cells and sensory (dorsal root and trigeminal gan-
glia), sympathetic (cervical superior ganglia),
parasympathetic (ciliary and pelvic parasympathet-
ic ganglia) and enteric ganglionic cells, statistical
analysis was performed in both human and rat sam-
ples by the Kruskal-Wallis test and Dunn’s multiple
comparison test.A p of 0.05 was considered signif-
icant.
In order to verify the immunohistochemical speci-
ficity of the reaction, absorption tests were also
performed through incubation with the N-terminal
peptides used to generate the antiserum for 2 hours
at room temperature.
Results 
In both humans (Figure 1) and rats (Figure 2),
NTR1 immunostaining was found in all the periph-
eral ganglia and carotid bodies examined. Ganglion
and glomic cell immunostaining was eliminated
when antiserum, preabsorbed with its peptide anti-
gen,was used (Figures 1B,1G,2B,2G).As regards
the subcellular location of NTR1 immunostaining,
in human superior cervical ganglia the percentage
of nuclear positivity on the total was 34.2±16.3%.
In rat superior cervical ganglia and in sensory,
parasympathetic and enteric ganglia of both
humans and rats, NTR1 positivity was almost only
found in the nuclei of ganglion cells.In sensory gan-
glia, weak/moderate nuclear immunostaining was
also found in some satellite cells.Positivity involved
both A- and B-cells of the sensory ganglia, without
statistically significant differences.
In both humans and rats, immunohistochemistry
revealed the coexistence of both NTR1-positive and
-negative type I cells in all specimens examined.
When present, NTR1 immunoreactivity was
intense, and distributed in the cytoplasm or nucle-
us.The percentage of nuclear NTR1 immunostain-
ing on the total was higher in rats (65.4±12.9%)
than in humans (13.9±11.1%; p<0.01). A prelim-
inary analysis of subpopulations of type I cells did
not reveal any statistically significant differences
between dark, light or pyknotic cells (p>0.05).
Immunostained cells were distributed in both the
center and periphery of the lobules.Type II cells did
not show immunostaining.
In both humans and rats, the Kruskal-Wallis test
revealed that the differences in NTR1 immunos-
taining between the structures examined were sta-
tistically significant (p<0.001 and p=0.03, respec-
tively).In humans,Dunn’s multiple comparison test
revealed that NTR1 immunostaining in sensory
ganglia (69.2±10.7%) was higher with respect to
parasympathetic ganglia (52.1±14.1%, p<0.01),
enteric ganglia (51.9±10.4%,p<0.01) and carotid
bodies (45.6±9.2%, p<0.001). Statistically signif-
icant differences were not found between pelvic
sympathetic and parasympathetic ganglia. In rats,
NTR1 immunostaining was significantly higher in
sensory ganglia than carotid bodies (73.0±13.1%
versus 50.8±6.8%, p<0.001) (Figure 3).
Mean percentages (± SD) of NTR1 immunos-
tained ganglion cells were significantly higher with
respect to human specimens in rat superior cervical
(72.4±11.4% versus 57.4±11.6%, p<0.05) and
enteric ganglia (64.6 ± 6.1% versus 51.9±10.4%,
p<0.05). NTR1 immunostaining of human pelvic
parasympathetic ganglia (52.1±14.1%) did not
significantly differ from immunostaining of rat cil-
iary ganglia (59.4±14.0%).
Discussion
NT has been found in the preganglionic axon ter-
minals of the cat sympathetic paravertebral and
prevertebral ganglia, but no NT immunoreactivity
was detected in principal ganglion cells (Heym et
al., 1984; Caverson  et al., 1989; Maher  et al.,
1994; Zetina  et al., 1999). Functional studies
reveal release of NT from preganglionic axon ter-
minals after stimulation (Caverson et al., 1989;
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Figure 1. Anti-NTR1 immunohistochemistry in humans - Sections of superior cervical (A-B), trigeminal (C), pelvic parasympathetic (D),
enteric (E) ganglia and carotid bodies (F-G), showing selective positivity of ganglionic cells (A, C-E) and glomic type I cells (F), while
immunostaining is largely eliminated in negative controls (B, G), performed through absorption with the N-terminal peptides used to gen-
erate the antiserum. Scale bars = 30 µ µm. 139
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Figure 2. Anti-NTR1 immunohistochemistry in rats - Sections of superior cervical (A-B), trigeminal (C), ciliary parasympathetic (D), enteric
(E) ganglia and carotid bodies (F-G), showing selective positivity of ganglionic cells (A, C-E) and glomic type I cells (F), while immunos-
taining is largely eliminated in negative controls (B, G) performed through absorption with the N-terminal peptides used to generate the
antiserum. Scale bars = 30 µ µm.Maher et al., 1994) and excitation of sympathetic
ganglion cells by exogen neurotensin (Bachoo and
Polosa, 1988). Moreover, anti-NT immunohisto-
chemistry shows NT internalization in ganglion
cells after stimulation of preganglionic fibers, and
this phenomenon is partially blocked by the NT
antagonist SR48692 (Zetina et al., 1999). NT-
immunoreactive fibers have also been found in
mammalian parasympathetic intracardiac ganglia
(Weihe and Reinecke,1981;Reinecke et al.,1982),
and sections from rat nodose ganglia incubated
with 125I-NT exhibit dense radioautographic label-
ing of 15% of ganglion cells, with nuclear sparing
(Kessler and Beaudet, 1989). NT-positive fibers
have also been detected in canine submucous and
myenteric ganglia (Buchan and Barber, 1987) and
NT binding sites have been found, through autora-
diography, in porcine (Seybold et al., 1990) and
human (Azriel and Burcher, 2001) submucous and
myenteric ganglia. Although the above studies
strongly suggest the presence of high-affinity NT
receptors on sympathetic, parasympathetic and
enteric ganglion cells, this is the first work which
identifies NTR1 in rat and human ganglia by
immunohistochemistry. Nuclear location of NTR1
has also been reported in other cell types (Boudin
et al., 1998; Dana et al., 1989; Feldberg et al.,
1998;Toy-Miou-Leong et al., 2004). For instance,
electron microscopy analysis of the distribution of
NTR1 in rat substantia nigra by immunohistochem-
istry (Boudin et al., 1998;Toy-Miou-Leong et al.,
2004) and autoradiography (Boudin et al., 1998)
has revealed the strongest NTR1 immunoreactivity
and the highest number of 125I-NT binding sites in
the nucleus with respect to other somatic struc-
tures.Mast cells have also been found to show par-
ticularly intense anti-NTR1 nuclear immunostain-
ing (Feldberg et al., 1998). In the literature,
nuclear location of NTR1 has mainly been ascribed
to internalization of the receptor (Boudin et al.,
1998;Feldberg et al.,1998;Toy-Miou-Leong et al.,
2004). NTR contains a strong nuclear targeting
signal (Feldberg et al., 1998), and it has also been
proposed that nuclear internalization of NT ligated
to its receptor plays a role in the production of
long-term genomic effects (Laduron, 1992).
Nuclear localization has also been described for
other G-protein-coupled receptors, such as
angiotensin type 1, VIP, opioid, prostaglandin, and
muscarinic receptors. However, it has also been
alternatively hypothesized that nuclear location of
NTR1 could be ascribed to the presence of neosyn-
thesized receptors, because the nuclear envelope
has long been considered a major site of protein
synthesis (Boudin et al., 1998). In the present
work, suppression of nuclear immunostaining after
absorption tests (Figures 1 and 2) confirms the
specificity of our results.
Dorsal root ganglia are known to express differ-
ent neurotransmitter receptors, such as nicotinic,
muscarinic, glutamate and opioid receptors. NT
immunoreactivity has also been found in the neu-
rons of cat, dog, primate, sloth and rat dorsal root
ganglia (Yaksh et al., 1988; Zhang et al., 1996).
Electrophysiological studies on extirpated rat dor-
sal root ganglia after NT exposure showed outward
and inward currents in C- and A-types neurons,
respectively, suggesting the expression of different
types of receptors (Xu et al., 1997). Inward cur-
rents in response to NT were also found in guinea-
pig dorsal root ganglia (Kawarada et al.,2000).In
situ hybridization revealed expression of NTR1
mainly in small sensory neurons of rat dorsal root
ganglia (Zhang et al., 1995), and immunofluores-
cence analysis revealed the expression of NTR2 in
both small and large cells (Sarret et al.,2005).We
also confirmed by immunohistochemistry NTR1
expression in sensory ganglion cells, and nuclear
NTR1 location supports internalization,also in this
structure. In addition, in both humans and rats it
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Figure 3. Mean values (± SD) of percentages of NTR1 immunore-
activity in ganglionic  and glomic type I cells of humans and rats.
Sensory ganglia: trigeminal and dorsal root ganglia. Sympathetic
ganglia: superior cervical ganglia (pelvic sympathetic ganglia not
considered). Parasympathetic ganglia: pelvic parasympathetic
ganglia in humans and ciliary ganglia in rats. Enteric ganglia: sub-
mucous and myenteric ganglia. must be stressed that the sensory ganglia showed
the highest NTR1 immunostaining among the dif-
ferent structures examined.
Many neurotransmitters and neuromodulators
have been identified in glomic cells, such as
dopamine, serotonin, noradrenaline, adrenaline,
acetylcholine, adenosine, met- and leu-enkephalins,
neuropeptide Y, CGRP, galanin, endothelins,
bombesin, NO and adrenomedullin (Bairam and
Carroll, 2005; Porzionato  et al., 2006, 2008a,
2008b). NT occurrence and distribution has been
studied by radioimmunoassay (Heath et al., 1988),
immunohistochemistry (Heym and Kummer, 1989)
and immunogold techniques (Smith et al., 1990).
In human carotid bodies, radioimmunoassay
showed higher levels of NT expression than VIP and
substance P,and lower levels of bombesin,met- and
leu-enkephalin (Heath et al., 1988). The immuno-
gold technique revealed the weakest immunoreac-
tivity for neurotensin with respect to the other neu-
ropeptides (Smith et al., 1990). A species-specific
pattern of NT expression was also reported, with
NT immunolabeling only in beagle glomus cells
among various animal species (Heym and Kummer,
1989). The location of NTR1 in the carotid body
has never been investigated before, so that our
study demonstrates for the first time the selective
expression of NTR1 in human and rat type I cells.
In some cases, immunoreaction was cytoplasmic
and in others nuclear, thus also confirming NT
internalization in the carotid body.The higher cyto-
plasmic NTR1 positivity in humans than in rats
may be explained on the basis of the different kinet-
ics of internalization, or longer post-mortem inter-
vals.Thus, NT produced by type I cells may act in
an autocrine or paracrine way on the same cell
type. It is possible that NT acting on type I cells
also derives from NT-positive sympathetic or
parasympathetic fibers innervating type I cells,
although there is no direct evidence of this in the
literature. NT probably plays a modulatory role on
chemoception by type I cells, as the neuromodula-
tory effects of NT have already been proposed in
ganglion transmission (Bachoo and Polosa, 1988).
Further functional studies will be necessary to
understand the effect of NT in glomic cells.Binding
of NT to NTR1 stimulates phosphorylation of ERK
and AKT (Hassan et al., 2004) and probably con-
tributes to the activation of ERK and AKT sig-
nalling pathways in the carotid body and peripheral
ganglia (Porzionato et al., In press). Cell line
PC12, which shows oxygen-sensing properties and
has been considered as a model for carotid body
function, cannot be used for investigation of NT
action, as these cells express and release neu-
rotensin (Tischler et al., 1991) but seem not to
show functional NTR (Caillaud et al., 1995).
However, it is intriguing to note that NT attenuates
dopamine-induced inhibition of midbrain dopamine
neurons (Seutin et al., 1989; Shi et al., 1992), as
dopamine is the main glomic neurotransmitter. It
may be hypothesized that, also in the carotid body,
NT reduces the inhibitory effect of dopamine on
chemoception.
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